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ABSTRACT
Although quantitative EEG parameters, such as spectral band powers, are sensitive 
to centrally acting drugs in dose- and time-related manners, changes of the EEG 
parameters are redundant. It is desirable to reduce multiple EEG parameters to a few 
components that can be manageable in a real space as well as be considered as 
parameters representing drug effects. We calculated factor loadings from normalized 
values of eight relative band powers (powers of 0.5, 1.0∼2.0, 2.5∼4.0, 4.5∼5.5, 6.0
∼8.0, 8.5∼12.0, 12.5∼24.5, and 25∼49.5 Hz bands expressed as ratios of the 
power of 0.5-49.5 Hz band) of EEG during pre-drug periods (11:00∼12:00) by factor 
analysis and constructed a two-dimensional canonical space (reference canonical 
space) by canonical correlation analysis. Eight relative band powers of EEG produced 
by either physostigmine or yohimbine were reduced to two canonical scores in the 
reference canonical space. While changes of the band powers produced by 
physostigmine and yohimbine were too redundant to describe the difference between 
two drugs, locations of two drugs in the reference canonical space represented the 
difference between two drug’s effects on EEG. Because the distance between two 
locations in the canonical space (Mahalanobis distance) indicates the magnitude of 
difference between two different sets of EEG parameters statistically, the canonical 
scores and the distance may be used to quantitatively and qualitatively describe the 
dose-dependent and time-dependent effects and also tell similarity and dissimilarity 
among effects. Then, the combination of power spectral analysis and statistical 
analysis may help to classify actions of centrally acting drugs. 
Key words: EEG, power spectral analysis, factor analysis, canonical correlation analy-
sis, physostigmine, yohimbine
INTRODUCTION
    Quantitative  electroencephalography  (qEEG)  has 
been  applied  to  the  various  purposes:  to  charac-Drug-induced  State  in  Canonical  Space 55
terize  psychotropic  drug  effects  in  human  and 
animals (Herrmann, 1982), to develop sensitive bio-
markers  for  diagnosing  psychiatric  disorders  (John 
et  al.,  2007;  Leiser  et  al.,  in  press),  disease  pro-
gression  (Luckhaus  et  al.,  2008),  treatment  pro-
gnosis (Hansen et al., 2003), and to predict clinical 
efficacy  of  putative  psychoactive  substances  (Knott 
et  al.,  1996;  Parker  et  al.,  2001;  Galderisi,  2002). 
Particularly, it has been tried to develop methods for 
screening  clinical  effect  of  centrally  acting  drugs. 
    Drug-induced  EEG  changes  have  been  used  as 
an  indicator  of  drug  action.  The  qEEG  parameters 
such  as  power  spectrum  and  band  powers  are 
mostly used in evaluation of drug effects. There are 
several  limitations  in  using  the  qEEG  parameters 
for evaluation of drug effects (van Riezen and Glatt, 
1993).  Firstly,  drug  effects  on  multiple  qEEG 
parameters  can  not  be  simply  explained  because 
many drugs produce an increase/decrease power of 
same  bands  and  because  the  change  of  one  band 
power show non-linear  relationship  with drug doses 
and  also  co-vary  with  those  of  neighboring  bands. 
Secondly,  drug  effects  are  confounded  with  fluc-
tuation of vigilance level such as sleep-wake cycles 
which  affects  EEG  activity  profoundly.  Then,  drug 
effects  can  not  be  separated  from  the  changes  of 
background  activity. 
    To  overcome  the  first  limitation,  multivariate  stati-
stical  methods  have  been  used  to  extract  a  few 
components  which  changes  are  mostly  related  to 
drug effects and reflect dose-effect relationship. For 
example,  a  set  of  band  powers  produced  by 
standard  drugs  having  already  known  mechanism 
or  belong  to  certain  classes,  a  reference  data  set, 
is fed as input data to the discriminant analysis and 
a few components which well described the classes 
of known drugs are extracted (Fairchild et al., 1980; 
Dimpfel  and  Decker,  1984).  Then,  a  test  drug  is 
classified  to  a  certain  class  by  the  rule  constructed 
from  the  reference  data  set.  Although  it  has  been 
used  widely  for  the  classification  of  the  psycho-
active  drugs,  it  requires  a  reference  data  set  from 
standard  psychoactive  drugs  having  known  clinical 
actions.  If  the  data  from  additional  standard  drugs 
have  been  added  to  the  reference  data  set,  the 
classification  rule  should  be  modified.  Different  set 
of standard psychoactive drugs used in building the 
reference  data  set  also  gives  different  classification 
rule  even  though  the  same  analysis  steps  and 
procedures  are  used.  Then,  to  build  a  ubiquitous 
reference  data  set,  a  standard  set  of  behavioral 
states which is independent to the sets of standard 
drugs,  can  be  used. 
    To overcome the second limitation, vigilance con-
trolling methods have been devised. For example, a 
treadmill  running  was  used  to  maintain  a  certain 
level of vigilance during the recording (Krijzer et al., 
1993).  However,  this  and  other  vigilance  controlling 
procedures  can  not  keep  the  level  of  vigilance 
constant anyhow because of natural sleep pressure 
as well as drug effects such as sedation or stimula-
tion which directly affect vigilance level (Lee, 1999). 
Here,  we  considered  that  the  drug  effects  on  the 
EEG  include  EEG  changes  from  natural  fluctuation 
and  drug  effects  on  EEG  and  interactions  between 
them. 
    Therefore,  we  proposed  band  powers  of  EEG 
during  natural  sleep-wake  cycles  can  be  used  as 
reference  data  set  which  is  fed  to  multivariate 
statistics to produce a few components representing 
a state and the fluctuation itself of vigilance level is 
considered  as  basic  components  of  a  state.  To 
maintain the average vigilance of reference data set 
to a certain level, we chose EEG signals during the 
same period (11:00∼12:00) of the day before drug 
administration. Then, the reference canonical space 
was  constructed  by  factor  analysis  and  canonical 
correlation  analysis  and  the  EEG  effects  of  phy-
sostigmine,  an  anticholinesterase  to  enhance  cho-
linergic  neurotransmission,  and  yohimbine,  an 
alpha2-adrenergic  receptor  blocker  to  enhance 
adrenergic  transmission,  were  compared  in  the 
canonical  space  whether  their  effects  could  be  well 
differentiated. 
MATERIALS  AND  METHODS
Animals
    Eighteen  male  Sprague-Dawley  rats  (Samtaco, 
Osan,  Korea)  weighing  357∼494  g  (420±43  g) 
were  used.  Each  two  animals  were  housed  in  a 
plastic  cage  (28×42×18  cm)  before  surgery.  Each 
animal  was  housed  in  a  cage  after  surgery.  They 
were maintained in a controlled environment through-
out the study: 22∼24
oC ambient temperature, 12：
12  hour  light-dark  cycle  (light  on  from  7:00  to 56 Maan-Gee  Lee,  et  al.
19:00),  with  a  commercial  food  and  tap  water 
available ad libitum except on the day of recording. 
The  rats  were  sacrificed  by  an  overdose  of  CO
2 
inhalation  after  the  completion  of  the  experiment. 
Experiments  were  carried  out  in  accordance  with 
the National Institutes of Health Guide for the Care 
and  Use  of  Laboratory  Animals. 
Surgery
    Surgical  procedure  was  similar  to  those  in  our 
previous study (Jang et al., 2009). In brief, epidural 
screw  electrodes  (tip  diameter  ∼1.0  mm)  for  EEG 
recording  were  implanted  under  ketamine  (75 
mg/kg, i.p.) and xylazine (5 mg/kg, i.p.) anesthesia. 
After the rats showed no movement in response to 
a  tail-pinch,  the  rats  were  placed  in  a  stereotaxic 
apparatus  (David  Kopf  Instruments  Inc.,  Tujunga, 
CA,  USA).  The  midline  scalp  was  locally  anes-
thetized  with  2%  lidocaine,  incised,  and  the  soft 
tissue  over  skull  surface  was  removed.  Six  small 
holes were drilled bilaterally in the frontal bone (2.5 
mm  anterior  and  1.25  mm  lateral  to  bregma),  the 
parietal  bone  (6  mm  posterior  and  5  mm  lateral  to 
bregma) and the interparietal bone (3 mm posterior 
and 2 mm lateral to lambda) without perforating the 
dura  mater  using  a  low-speed  drill  (diameter  0.8 
mm) under surgical microscope. Four stainless steel 
screws  were  inserted  into  the  holes  in  the  frontal 
and  parietal  bones  for  EEG  recording  from  the 
frontal  and  parietal  cortices,  respectively.  Two 
additional screws were inserted into the holes in the 
interparietal  bones  for  reference  and  ground 
electrodes.  The  electrodes  with  connecting  pins 
were  arranged  together  in  3×2  matrices  and  fixed 
over  the  skull  with  dental  cement.  The  rats  were 
allowed at least 7 days to recover from the surgery 
before  recording. 
EEG  recording
    At  the  day  of  recording,  two  rats  were  placed  in 
the recording chamber and connected to the swivel 
before  10:00.  EEG  signals  were  recorded  con-
tinuously  from  10:00  to  17:30.  The  4  signals  from 
the  frontal  and  parietal  cortices  were  recorded 
monopolarly with respect to the reference electrode. 
The  signals  were  fed  to  the  amplifier  (AxoProbe 
410  and  CyberAmp  380,  Axon  Instruments  Inc., 
Foster  City,  CA,  USA),  where  they  were  amplified 
10,000  times  and  filtered  with  low-pass  60  Hz  and 
high-pass  1  Hz).  They  were  saved  to  a  PC  by  a 
data  acquisition  board  (DigiData  1200A,  Axon  In-
struments Inc., Foster City, CA, USA) at a sampling 
rate  200  Hz. 
Drugs
    Physostigmine sulfate  2H2O (Tocris,  Ballwin,  MO, 
USA)  and  yohimbine  hydrochloride  (Sigma  Chemi-
cal  Co.,  St.  Louis,  MO,  USA)  were  purchased  as 
commercial  products.  Physostigmine  sulfate  and 
yohimbine  hydrochloride  were  freshly  dissolved  in 
distilled  water  before  the  first  dosing.  The  admini-
stration  volume  was  0.5  or  1.0  ml/kg. 
Treatment
    The  rats  were  randomly  assigned  to  two  groups 
(n=10  for  physostigmine  treatment,  Phy;  n=8  for 
yohimbine  treatment,  Yoh).  Drugs  were  always 
administered at 12:00, 14:00 and 16:00±5 min with 
each  of  three  doses:  0.2,  0.5  and  1.0  mg/kg  phy-
sostigmine  and  1,  2  and  5  mg/kg  yohimbine  intra-
peritoneally. 
Power  spectrum  analysis
    The  raw  EEG  signals  were  visually  inspected 
prior  to  analysis  and  10-sec  EEG  epochs  with 
artifacts  were  excluded  from  analysis.  The  EEG 
signals  of  11:00∼12:00  (Pre)  before  and  eight 
15-min  segments  (numbered  with  S1,  S2,  S3,  S4, 
S5,  S6,  S7  and  S8)  after  drug  injections  at  12:00, 
14:00 and 16:00 were analyzed by power spectrum 
analysis.  The  EEG  signals  of±5  min  around  drug 
injection  (beginning  5-min  of  the  first  and  ending 
5-min  of  the  eighth  segments)  were  excluded  from 
analysis  because  of  behavior  disturbed  by  experi-
mental  procedure  for  injection.  Ten  power  spectra 
were  calculated  by  using  a  fast  Fourier  transform 
from  10  Hanning-windowed  2-sec  FFT  epochs 
(1-sec overlap) of one 10-sec EEG epoch and then 
averaged  to  a  power  spectrum.   
    All  the  power  spectra  from  one  animal  were 
normalized with average total power (0.5∼49.5 Hz) 
of  its  Pre  values.  The  spectrum  was  divided  to  8 
frequency bands (1, 0.5; 2, 1.0∼2.0; 3, 2.5∼4.0; 4, 
4.5∼5.5;  5,  6.0∼8.0;  6,  8.5∼12.0;  7,  12.5∼24.5; 
and  8,  25∼49.5  Hz).  The  relative  band  powers 
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Fig.  1. P o w e r  s p e c t r a  o f  E E G  f r o m  
the  frontal  cortex  (A,  C)  and  the 
parietal  (B,  D)  cortex  of  the  second 
segment (S2, 15∼30 min) after each 
dose  of  drugs.  Significant  changes   
in  powers  at  each  frequency  bin  of 
the  mean  spectra  were  produced  by 
3  doses  of  physostigmine  (Phy:  0.2, 
0.5  and  1.0  mg/kg)  (A,  B)  and  of 
yohimbine  (Yoh:  1,  2  and  5  mg/kg) 
(C, D). *p＜0.05, significantly different 
from the Pre. FC: frontal cortex, PC: 
parietal  cortex,  S2:  the  2
nd  segment 
(15∼30  min  after  a  dose).
8 frequency bands to the total power. The absolute 
band powers were expressed as log10 of powers of 
5 frequency bands (DE, 0.5∼4.0; TH, 4.5∼5.5, 6.0
∼8.0; AL, 8.5∼12.0; BE, 12.5∼24.5; GA 25∼49.5; 
and  TO,  0.5∼49.5  Hz).  All  the  calculations  were 
performed by custom-made programs using MatLab 
(MathWorks  Inc.,  Natick,  MA,  USA). 
Statistical  analysis
    Data were expressed as mean for power spectra 
and  Mahalanobis  distance,  mean  ±0.5×standard 
deviation (SD) for the absolute band powers, mean 
±standard  error  of  mean  (SEM)  for  the  relative 
band  powers  and  mean±95%  confidence  limit  of 
mean for canonical components. The power spectra 
were compared with multiple t-tests every frequency 
bin between each drug dose and Pre. The absolute 
band powers were analyzed by a repeated-measure 
ANOVA  and  a  Tukey  test  for  time.  The  eight 
relative  band  powers  of  all  epochs  of  Pre  were 
used  as  input  variables  for  a  factor  analysis  and  a 
canonical correlation analysis. Resultant factor load-
ings  of  variables  and  eigenvectors  were  used  to 
calculate  two-dimensional  canonical  scores  of  all 
the  EEG  epochs  of  the  recordings.  The  canonical 
components  were  compared  by  an  ANOVA  and  a 
Tukey  test  with  times  and  confidence  intervals  of 
the  mean  were  compared  among  drugs  and  dosa-
ges.  The  Mahalanobis  distance  (McLachlan,  1999) 
which  is  expressed  by  square  of  the  distance 
between  two  locations  in  the  canonical  space,  was 
calculated  from  two  canonical  variables.  All  the 
calculations  were  performed  by  custom-made  pro-




    Significant  changes  in  powers  at  each  frequency 
bin of the mean spectra were produced by 3 doses 
of physostigmine (Phy, 0.2, 0.5 and 1.0 mg/kg) and 
of  yohimbine  (Yoh,  1,  2  and  5  mg/kg)  (Fig.  1).  No 
significant  difference  was  observed  between  doses 58 Maan-Gee  Lee,  et  al.
Fig.  2. Time trends of the absolute band powers of EEG fromt the frontal cortex (FC). All doses of physostigmine (Phy: 0.2, 0.5 and 1 
mg/kg, i.p.) produced decreases of all other band powers but GA band power which was increased. In contrast, significant changes were 
observed  differently  by  some  doses  of  yohimbine  (Yoh:  1,  2  and  5  mg/kg,  i.p.)  according  to  the  bands.  *p＜0.05,  significantly  different 
from the Pre. DE: delta, TH: theta, AL: alpha, BE: beta, GA: gamma, and TO: total power, Pre: a period of 11:00∼12:00, S1 to S8: the 
first  to  8
th  segments  (every  15  min  period  after  a  dose).
in both drugs. Maximum effect was observed by the 
highest  dose  of  physostigmine,  while  it  was  ob-
served  by  the  lowest  dose  of  yohimbine.  Shown  in 
maximal  effect  of  physostigmine,  powers  were 
significantly  decreased  at  the  lower  frequencies 
below 22 Hz in the frontal cortex and 25 Hz in the 
parietal  cortex,  and  they  were  increased  at  the 
higher  frequencies  above  32  Hz  in  the  frontal  and 
parietal  cortices  (Fig.  1A,  B).  In  contrast,  shown  in 
maximal  effect  of  yohimbine,  powers  were  signifi-
cantly decreased at the lower frequencies below 20 
Hz  in  the  frontal  cortex  and  17  Hz  in  the  parietal 
cortex,  and  they  were  increased  at  the  higher 
frequencies  above  37  Hz  only  in  the  frontal  cortex 
(Fig.  1C,  D). 
Absolute  band  powers
    All  doses  of  physostigmine  produced  decreases 
of all other band powers but GA band power which 
was  increased,  while  significant  changes  were 
observed  differently  by  some  doses  of  yohimbine 
according  to  the  bands  in  both  the  frontal  and 
parietal  cortices  (Figs.  2,  3).  In  the  frontal  cortex 
(Fig.  2  Left),  significant  change  was  clearly  shown 
from  the  first  segment  of  5∼15  min  after  the 
highest  dose  injection  in  most  bands  (TH,  AL,  BE 
and  GA),  but  was  delayed  in  DE  band  from  the 
third  segment  of  30∼45  min  after  injection.  This Drug-induced  State  in  Canonical  Space 59
Fig. 3. Time trends of the absolute band powers of EEG fromt the parietal cortex (PC). Note that all doses of physostigmine (Phy: 0.2, 
0.5  and  1  mg/kg,  i.p.)  produced  decreases  of  all  other  band  powers  but  GA  band  power  which  was  increased.  In  contrast,  note  that 
significant changes were observed differently by some doses of yohimbine (Yoh: 1, 2 and 5 mg/kg, i.p.) according to the bands. *p＜0.05, 
significantly different from the Pre. DE: delta, TH: theta, AL: alpha, BE: beta, GA: gamma, and TO: total power, Pre: a period of 11:00∼
12:00,  S1  to  S8:  the  first  to  8
th  segments  (every  15  min  period  after  a  dose).
lasted in a range of 45∼75 min. Most band powers 
seemed  to  be  changed  proportion  to  the  doses.  In 
the frontal cortex (Fig. 2 Right), the highest dose of 
yohimbine  induced  decreases  of  power  of  some 
bands  (DE,  TH,  AL  and  TO)  with  longer  duration 
while the intermediate dose induced larger magnitude 
but shorter duration of decrease in DE, TH, AL, BE 
and  TO  band  powers.  Significant  changes  in  DE, 
TH and TO bands lasted for approximately 120 min 
from  the  start  after  drug  injection  to  the  end  of 
recording  at  the  largest  dose.
    In  the  parietal  cortex,  similar  changes  as  the 
frontal  cortex  were  observed  (Fig.  3  Left).  Different 
from the frontal cortex, DE band power changed at 
the  start  after  drug  injection  and  TH  band  power 
did  not  significantly  decreased  after  injection  with 
the  highest  dose.  TH  band  power  was  significantly 
decreased  with  the  lowest  dose  of  physostigmine. 
Significant  changes  with  the  largest  dose  of 
yohimbine  were  observed  in  DE,  TH,  AL  and  TO 
and  lasted  15  to  60  min  depending  on  the  bands 
which  is  shorter  than  the  duration  in  the  frontal 
cortex  (Fig.  3  Right). 
Projections  to  the  reference  canonical  space 
of the EEG from the cortex of the same group
    Despite  some  similarity  and  other  dissimilarity 
between  physostigmine  and  yohimbine  were  men-60 Maan-Gee  Lee,  et  al.
Fig. 4. Projections to the reference canonical space of the EEG from the frontal cortex. The data sets of relative band powers fed to the 
multivariate  statistics  were  shown  on  A1  to  A3.  Corresponding  projection  on  the  two-dimensional  canonical  space  for  the  frontal  cortex 
were depicted on B1 to B3. The mark of the center (0, 0) of each graph is the location of Pre and other symbol represents each of eight 
15-min  segments  after  one  dose  of  drug  injection.  A1  and  B1.  low  dose  (Phy:  0.2  mg/kg  and  Yoh:  1  mg/kg);  A2  and  B2.  intermediate 
dose  (Phy:  0.5  mg/kg  and  Yoh:  2  mg/kg);  and  A3  and  B3.  high  dose  (Phy:  1  mg/kg  and  Yoh:  5  mg/kg).  Large  arrows  on  B1  to  B3 
display the direction and distance of projection of the first segment from the center. FC: frontal cortex, Phy: physostigmine, 1 to 8: eight 
bands,  Pre:  a  period  of  11:00∼12:00,  S1  to  S8:  the  first  to  8
th  segments  (every  15  min  period  after  a  dose),  C1  and  C2:  canonical 
variables.
tioned,  evaluation  of  the  difference  of  the  overall 
drug  effects  was  impossible  due  to  irregularity  and 
complexity  of  the  changes  among  multiple  band 
powers. Therefore, the factor analysis based on the 
effects  observed  in  the  8  relative  band  powers  in 
each  cortex  during  one-hour  pre-drug  period  (Pre) 
resulted  in  factor  loadings  to  calculate  common 
factors  which  may  represent  drug  effects  on  the 
EEG  and  were  used  to  measure  the  magnitude  of 
the  effects,  and  then  canonical  correlation  analysis 
resulted  in  eigenvector  for  the  two-dimensional 
reference  canonical  space. 
    The data sets  of relative band powers  fed to the 
multivariate statistics were shown on the left panels 
of  Figs.  4  and  5.  Corresponding  projection  on  the 
two-dimensional  canonical  space  for  each  cortex Drug-induced  State  in  Canonical  Space 61
Fig.  5.  Projections  to  the  reference  canonical  space  of  the  EEG  from  the  parietal  cortex.  The  data  sets  of  relative  band  powers  fed  to 
the  multivariate  statistics  were  shown  on  A1  to  A3.  Corresponding  projection  on  the  two-dimensional  canonical  space  for  the  parietal 
cortex were depicted on B1 to B3. The mark of the center (0, 0) of each graph is the location of Pre and other symbol represents each 
of  eight  15-min  segments  after  one  dose  of  drug  injection.  A1  and  B1.  low  dose  (Phy:  0.2  mg/kg  and  Yoh:  1  mg/kg);  A2  and  B2. 
intermediate  dose  (Phy:  0.5  mg/kg  and  Yoh:  2  mg/kg);  and  A3  and  B3.  high  dose  (Phy:  1  mg/kg  and  Yoh:  5  mg/kg).  Large  arrows  on 
B1 to B3 display the direction and distance of projection of the first segment from the center. PC: parietal cortex, Phy: physostigmine, 1 
to  8:  eight  bands,  Pre:  a  period  of  11:00∼12:00,  S1  to  S8:  the  first  to  8
th  segments  (every  15  min  period  after  a  dose),  C1  and  C2: 
canonical  variables. 
were depicted on the right panels of Figs 4. and 5. 
The mark of the  center  (0,  0)  of each graph is  the 
location  of  Pre  and  others  represented  at  15-min 
segments  after  one  dose  of  drug  injection. 
    In  the  frontal  cortex,  the  projections  of  the 
canonical variables after all doses of physostigmine 
injection  started  at  the  location  down  and  left  from 
the  center  of  the  space  and  then  returned  to  the 
center with times (Fig. 4 Left B1 to B3). In contrast, 
the  projections  after  the  higher  doses  of  yohimbine 
(2 and 5 mg/kg) started at the location up and right 
from  the  center  and  did  not  returned  to  the  center 
but ended at the location up from the center or up 
and  slightly  left  from  the  center  (Fig.  4  Right  B2 
and  B3).  The  projections  after  the  lowest  dose  (1 
mg/kg)  returned  to  the  center  (Fig.  4B1). 62 Maan-Gee  Lee,  et  al.
Fig.  6.  (A)  Factor  loadings  for  the 
reference  canonical  space  for  the 
frontal  cortex  (left)  and  for  the  pari-
etal  cortex  (right).  (B)  Time  trend  of 
Mahalanobis  distance  in  the  refer-
ence  canonical  space  for  the  frontal 
cortex  (left)  and  for  the  parietal 
cortex  (right)  before  and  after  drug 
administration.  Maximal  distances  of 
projections  of  frontal  EEG  were  at 
S1 in both physostigmine and yohim-
bine. However, maximal distances of 
projections  of  parietal  EEG  were  at 
S1  in  yohimbine  but  at  S4  in  phy-
sostigmine.  Ref:  reference,  FC:  frontal 
cortex,  PC:  parietal  cortex,  1  to  8: 
eight  bands,  Pre:  a  period  of  11:00
∼12:00,  S1  to  S8:  the  first  to  8
th 
segments  (every  15  min  period  after 
a  dose),  C1  and  C2:  canonical  vari-
ables. 
    In  the  parietal  cortex,  the  projections  started  at 
the  location  right  and  slightly  down  from  the  center 
and  then  returned  to  the  center  with  times  (Fig.  5 
Left  B1  to  B3).  The  projections  after  all  doses  of 
yohimbine started at the location down or down and 
left  from  the  center  and  did  not  returned  to  the 
center  with  times  but  ended  at  the  location  down 
and  left  from  the  center  (Fig.  5  Right  B1  to  B3).
Mahalanobis  distances
    The Mahalanobis distance is expressed by square 
of the distance between two locations and indicates 
dissimilarity  of  the  states,  that  is,  projection  to  the 
reference  canonical  space  of  the  EEG  parameters 
after  drug  injection.  In  the  reference  canonical 
space  constructed  by  the  EEG  parameters  in  the 
frontal  cortex  before  drug  administration,  the  pro-
jections  after  1  mg/kg  physostigmine  or  1  mg/kg 
yohimbine  were  presented.  Maximal  distances  of 
projections  of  frontal  EEG  were  at  S1  in  both 
physostigmine  and  yohimbine  (Fig  6A  Left).  How-
ever,  maximal  distances  of  projections  of  parietal 
EEG  were  at  S1  in  yohimbine  but  at  S4  in  phy-
sostigmine  (Fig.  6B  Left). 
DISCUSSION
    The  present  study  demonstrates  that  the  relative 
band  powers  of  EEG  during  natural  sleep-wake 
cycles  were  used  as  a  reference  data  set  repre-
senting  standard  states  including  all  natural  levels 
of  vigilance  and  the  resulted  reference  canonical 
space was well used for differentiating psychotropic 
agents and for time trend of their actions. Thus, the 
EEG effects of physostigmine, an anticholinesterase 
to enhance cholinergic neurotransmission, and those 
of yohimbine, an alpha2-adrenergic receptor blocker 
to  enhance  adrenergic  neurotransmission,  were 
differentiated  quantitatively  and  qualitatively  by  the 
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and  direction  from  its  center. 
    In  general,  it  is  believed  that  the  action  of  psy-
chotropic  drugs  on  the  specific  neurotransmitter 
system(s)  or  receptors  induces  specific  changes  in 
power  spectral  profile.  In  this  study,  physostigmine 
induced  a  spectral  profile  different  from  one  of 
pre-drug  state  and  also  from  yohimbine  in  some 
frequency  bins  but  not  in  others  as  power  at  each 
frequency  bin  of  power  spectrum  was  compared. 
Some  characteristics  such  as  significant  power 
difference  over  a  wider  range  observed  after  phy-
sostigmine  than  yohimbine,  prominent  theta  peak 
disclosed  by  decreased  powers  around  the  peak, 
no  significant  power  differences  over  the  higher 
frequency  ranges  in  yohimbine  even  significant 
power  increases  observed  in  lower  dose  of  yohim-
bine  in  the  frontal  cortex,  and  etc.,  were  apparent 
in  visual  inspection.  But  the  description  of  drug 
induced  change  or  recording  regions  was  only 
possible  verbosely  in  every  frequency  bin. 
    After  data  reduction  from  the  power  spectrum  to 
the  absolute  powers  over  some  specific  frequency 
bands  which  are  divided  by  empirically  or  statisti-
cally  (Herrmann,  1982),  the  simpler  description  of 
drug  effects  was  possible.  For  example,  the  peak 
time of the band powers are different from different 
drugs  on  different  cortex.  This  may  indicate 
temporal pattern of pharmacokinetic characteristic of 
the  drugs  but  still  does  not  say  direct  relationship 
between  single  band  powers  and  drug  concen-
tration  on  the  action  site.  Some  researchers  use 
specific  EEG  parameters,  such  as  beta  spindle 
activity  or  beta  power  with  benzodiazepines  action 
as  indicator  of  drug  concentration  in  action  site 
(Mandema  et  al.,  1991).  Other  researchers  use  a 
delta  band  and  theta  band  during  specific  sleep 
state  as  indicator  of  different  action  mechanism  on 
the receptors (Xi and Chase, 2008). However, there 
are  subjective  and  empirical  selection  of  the  EEG 
parameters correlated with pharmacokinetic/pharma-
codynamic  actions  (Bol  et  al.,  2000). 
    Therefore, we used multivariate statistics whether 
we  can  describe  the  characteristics  of  drug  action 
potency  and  temporal  trend  with  simplicity  and 
quantitatively. We used the relative band powers for 
the  input  to  multivariate  statistics  because  they  are 
less  dependent  to  the  recording  setup  such  as 
amplifier  gain  and  electrode  impedance  than  the 
absolute  band  powers.  Even  though  information  of 
magnitude  of  power  may  be  removed,  the  power 
distribution  profile  of  EEG  induced  by  drugs  was 
conserved.  Then,  we  used  factor  analysis  and 
canonical  correlation  analysis  in  order  to  extract 
from  8  relative  band  powers  to  two  meaningful 
parameters  which  can  be  easily  interpreted  by 
human  brain.  We  showed  that  the  action  at  a  time 
can  be  projected  on  the  canonical  space  con-
structed from a reference data set. As the reference 
data  set,  the  relative  band  powers  of  epochs  of 
EEG  from  the  cortex  during  pre-drug  period  of 
same  time  period  of  the  day  (11:00∼12:00)  were 
used.  It  includes  all  natural  levels  of  vigilance,  but 
the  state  as  a  whole  was  not  different  among 
animals (data not shown). That is, the same period 
of  the  day  included  all  the  natural  sleep-wake 
states  with  consistent  proportions  of  sleep-wake 
states  among  animal.  Then,  it  could  be  standard 
classes  for  the  reference  data  set.  Between 
different  cortices,  there  was  different  factor  loading 
for  the  canonical  variables,  which  may  reflect  the 
different  brain  state  between  the  brain  regions.   
    In  this  study,  we  did  not  used  standard  psycho-
tropic  drugs  belong  to  several  known  classes  as 
reference  data  sets  that  have  been  used  in 
classification  of  psychotropic  drugs  by  discriminant 
analysis  with  predefined  classes  (Itil  et  al.,  1979; 
Ruigt  et  al.,  1993;  Dimpfel,  2003).  Fairchild  et  al. 
(1975)  calculated  sleep-dependent  canonical  com-
ponents and residuals canonical correlation analysis 
from  EEG  of  representative  segments  of  visually 
classified  sleep  stages,  which  was  used  as  depen-
dant  variable,  and  then  calculated  two  sleep- 
independent  canonical  variables  from  the  residuals. 
Instead,  we  used  factor  analysis  to  calculate  factor 
loadings  from  the  data  sets  of  the  relative  band 
powers  of all  the  epochs  during normal  sleep-wake 
cycles, in  which  all  the epochs  were  considered  as 
all  different  classes  or  states,  and  then  canonical 
correlation  analysis  to  calculate  canonical  variables 
from  drug  induced  EEG  profile.  This  procedure  is 
not  affected  by  existence  of  very  few  standard 
drugs  in  predefined  classes.  Some  studies  have 
used  different  multivariate  statistical  analysis  such 
as  cluster  analysis  on  the  data  without  predefining 
the  class  to  classify  psychiatric  disorders  (John  et 
al.,  1983;  John  et  al.,  1992).  The  multivariate  stati-64 Maan-Gee  Lee,  et  al.
stical analysis not requiring predefined class can be 
more  realistic  procedure  to  investigate  the  corre-
spondence  between  the  definable  classes  and 
psychotropic  drugs  and  to  find  new  classes. 
    Since  different  drug  actions  on  specific  receptors 
and  neurotransmissions  result  in  different  EEG 
changes  and  then  they  result  in  different  projection 
locations, it is possible to suppose that the location 
in  the  canonical  space  represent  a  brain  functional 
state.  And  a  distance  in  the  canonical  space, 
Mahalanobis distance, indicates a magnitude of the 
difference  between  two  states  (McLachlan,  1999). 
After  physostigmine  administration,  the  farthest  pro-
jections  from  the  center  in  the  reference  canonical 
space  for  the  frontal  cortex  were  dose-dependant 
and  the  projection  of  the  segments  became  closer 
to  the  center  with  time  after  dose.  Similarly,  the 
farthest  projections  in  the  space  for  the  parietal 
cortex were also dose dependant and the projection 
returned  to  the  center  with  time.  The  direction  of 
the farthest projections was left and down from the 
center in the space for the frontal cortex while were 
right  from  the  center  in  the  space  for  the  parietal 
cortex. This does not explain what are the different 
action  on  the  different  cortex  but  may  still  indicate 
there  is  difference  in  action. 
    In contrast, the pattern of projections in the space 
after  yohimbine  was  different  from  that  of  physo-
stigmine.  The  farthest  projections  in  the  space  for 
the frontal cortex were up and right from the center 
similar to the physostigmine, but the farthest among 
them  was  observed  at  lowest  dose  of  yohimbine 
not  in  higher  doses.  The  projections  did  not  return 
to  the  center  but  moved  to  the  up  and  right  from 
the  center.  In  the  space  for  the  parietal  cortex,  the 
farthest  projection  was  observed  at  lowest  dose  of 
yohimbine  and  the  projections  did  not  return  to  the 
center  but  moved  to  left  from  the  center.  Three 
doses  were  administered  cumulatively  and  then 
pre-exposure  to  drug  may  affect  the  sensitivity  of 
the  neurotransmission.  These  results  may  indicate 
that pre-exposure to physostigmine does not modify 
the  sensitivity  of  the  cholinergic  neurotransmission 
but  pre-exposure  to  yohimbine  does  modify  the 
sensitivity  of  the  adrenergic  neurotransmission. 
    If  we  accept  that  a  location  in  the  canonical 
space represents a brain functional state and that a 
distance between two locations indicates magnitude 
of  a  difference  between  two  states,  we  could 
differentially  describe  the  effects  of  physostigmine 
and yohimbine. In the reference canonical space of 
the  frontal  cortex,  physostigmine  changed  the  nor-
mal functional state to a functional state of low and 
left  location  while  yohimbine  changed  to  a  state  of 
up  and  right  location.  In  the  reference  canonical 
space  of  the  parietal  cortex,  both  physostigmine 
and  yohimbine  changed  from  the  normal  functional 
state to a state of low and right location. It may be 
interpreted  that  two  drugs  produced  different  func-
tional  states  on  the  frontal  cortex  but  similar 
functional  state  on  the  parietal  cortex.  However, 
these  results  can  not  show  what  mechanism  of 
action  affect  differentially  on  the  different  cortex. 
    In  this  study,  it  may  be  possible  that  the  mag-
nitude  of  changes  produced  by  different  drugs  can 
be compared with Mahalanobis distances calculated 
in  the  reference  canonical  space.  The  effect  of  1 
mg/kg of physostigmine is similar to that of 1 mg/kg 
yohimbine  on  the  frontal  cortex  and  the  parietal 
cortex.  Both  drugs  produce  maximal  effect  at  the 
first  segment  after  drugs  on  the  frontal  cortex.  In 
contrast,  physostigmine  produces  maximal  effect  at 
the first segment after drug but yohimbine produces 
maximal effect at the 4-th segment after drug. Both 
drugs have bigger effects on the frontal cortex than 
the  parietal  cortex.  Temporal  changes  can  also  be 
compared. 
    Taken  together,  these  results  suggest  that  the 
EEG  effects  of  physostigmine  and  those  of  yohim-
bine can be compared quantitatively and qualitatively 
by  the  distance  and  direction  from  its  center  in  the 
reference  canonical  space. 
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